Evidence map›Paper›PMID 37368349›Full record

Trial reportThe Journal of infectious diseases2024

Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine: A Follow-up Study in Pakistan in 2020.

Ali Faisal Saleem, Sadia Parkar, Syeda Mahjabeen Zehra, Zaubina Kazi, Asma Pethani, Yiting Zhang, Bernardo A Mainou, Rocio Lopez Cavestany, Grace Macklin, Visalakshi Jeyaseelan and 1 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03286803 (Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03286803 phase4unknown statusnot on this map

Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan

TypeinterventionalSponsorAga Khan UniversityRan2017 to 2019Enrolled500ConditionsPoliovirus Vaccine, Inactivated, Poliomyelitis, Immunization, InfectionArmsInactivated Poliovirus vaccine
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ali Faisal SaleemDepartment of Paediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Sadia ParkarDepartment of Paediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Syeda Mahjabeen ZehraDepartment of Paediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Zaubina KaziDepartment of Paediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Asma PethaniDepartment of Paediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Yiting ZhangPopulation Immunity Laboratory, Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA.
Bernardo A MainouPopulation Immunity Laboratory, Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA.
Rocio Lopez CavestanyPolio Eradication, World Health Organization Geneva, Switzerland.
Grace MacklinPolio Eradication, World Health Organization Geneva, Switzerland.
Visalakshi JeyaseelanPolio Eradication, World Health Organization Geneva, Switzerland.
Ondrej MachPolio Eradication, World Health Organization Geneva, Switzerland.ORCID 0000-0001-9100-8312

Funding

Role of beta1 integrin in mammalian reovirus infection.F32AI080108 · NIAID · VANDERBILT UNIVERSITY · PI MAINOU, BERNARDO ALFREDO · 2008 to 2009
$97k
NIAID NIH HHS F32 AI080108World Health Organization 001
6 · The paper itself

Abstract

This was a follow-up study conducted in 2020 assessing changes in levels of type 2 poliovirus-neutralizing antibodies 2 years postimmunization in children who received inactivated poliovirus vaccine (IPV) in Karachi, Pakistan. Unexpectedly, the findings revealed an increase in seroprevalence of type 2 antibodies from 73.1% to 81.6% 1 year and 2 years after IPV, respectively. The increase in type 2 immunity could result from the intensive transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Karachi during the second year of IPV administration. This study suggests that the cVDPV2 outbreak detected in Pakistan infected large proportions of children in Karachi. Clinical Trials Registration . NCT03286803.

Indexed as

PoliomyelitisPoliovirusAntibodies, ViralChildFollow-Up StudiesHumansPakistanPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralSeroepidemiologic StudiesAntibodies, ViralPoliovirus Vaccine, InactivatedPoliovirus Vaccine, Oralduration of immunityinactivated poliovirus vaccinePakistanpoliovirusseroprevalence

Identifiers

PMID37368349
PMCPMC13381267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.